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Precis: Some progress has occurred in survival for liver cancer, but 5-year survival remains low, 
even for those diagnosed at localized stage. Given the low survival observed in all states, efforts 
directed at controlling well-established risk factors, such as hepatitis B may have the greatest 
impact on reducing the burden of liver cancer in the United States. 
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Abstract 
Background. Worldwide, liver cancer is a leading cause of death for both men and women. The 
number of Americans who are diagnosed with liver cancer and die from it has been rising slowly 
each year. We examined population-based survival, by state, race, and stage at diagnosis, using 
data from the CONCORD-2 study. Methods. We analyzed data from 37 state-wide registries, 
covering approximately 80% of the US population, for patients diagnosed during 2001-2009.  
Survival up to five years was adjusted for background mortality (net survival) using state- and 
race-specific life tables, and age-standardized using the International Cancer Survival Standard 
(ICSS) weights. Results. Liver cancer was diagnosed overall more often at the localized stage, 
with blacks being more often diagnosed at distant and regional stages than whites. Overall 5-year 
net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than 
blacks in both calendar periods (11.7% vs. 9.1% and 14.3% vs. 11.4%, respectively). During 
2004-2009, 5-year survival was 25.7% for localized stage, 9.5% for regional stage, and 3.5% for 
distant stage. Conclusion. Some progress has occurred in survival for liver cancer, but 5-year 
survival remains low, even for those diagnosed at localized stage. Efforts directed at controlling 
well-established risk factors such as hepatitis B may have the greatest impact on reducing the 
burden of liver cancer in the US. 
 
Keywords: cancer registries, survival, liver, hepatitis 
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Introduction 
Worldwide, liver cancer is the fifth most common cancer among men, the ninth most common 
cancer among women, and the second most common cause of cancer death for men and women 
combined (1). Recent reports from North America, Europe, and Japan showed that the incidence 
of hepatocellular carcinoma (HCC), the most common histological type, is increasing (2-5). The 
number of Americans who are diagnosed with and die from liver cancer each year has been 
rising slowly for several decades (6). In 2013, 21,143 men and 8,330 women were diagnosed 
with liver cancer, and 16,300 men and 7,732 women died from liver cancer (7). According to the 
2015 Annual Report to the Nation, United States (US) death rates for most cancer sites declined 
or were stable from 2003 to 2012 among men and women of each racial and ethnic, except for 
liver cancer, which increased for most racial and ethnic groups (8). Among men and women, US 
liver cancer incidence rates were highest among American Indian/Alaskan Natives, followed by 
Asian Pacific Islanders, and Hispanics. Liver cancer incidence rates among US men were more 
than twice those among US women (8).  
 
Chronic hepatitis B (HBV), Chronic hepatitis C (HCV), and cirrhosis all contribute to the risks 
associated with hepatocellular carcinoma. HBV and HCV infections account for an estimated 
78% of global HCC cases (9). In addition, excessive alcohol consumption, obesity, rare 
metabolic disorders, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD) are 
other known risk factors of liver cancer (10). Most cases of HCC are preventable. Methods to 
reduce the risk of liver cancer include evidence-based strategies or interventions related to the 
risks associated with hepatitis. Vaccination against hepatitis B infection for all infants at birth 
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and adults who may be at an increased risk, as well as testing for hepatitis C and linking patients 
to follow-up care after testing, leads to declines in HCC incidence (8). 
In contrast to many other cancers, the prognosis of patients with HCC is not highly correlated 
with tumor stage. Cirrhosis underlies the neoplasm in most cases and has major impact on the 
prognosis of patients with HCC (11).  The CONCORD-2 study reported survival for patients 
with cancer diagnosed from 1995 through 2009 in 67 countries, and enabled the comparison of 
survival of patients in the United States (US) with other countries (12).  Liver cancer survival 
was low in all countries. The 5-year age-standardized net survival from liver cancer was below 
20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in 
Mongolia and Thailand. Between 1995-99 and 2005-2009, five-year age-standardized net 
survival from liver cancer increased in the United States from 9% to 15%. This could possibly be 
due to improved viral hepatitis services and medical management.   
 
The purpose of the current study is to expand the CONCORD-2 study by reporting liver cancer 
survival in the United States using the largest data set available (80% US coverage), by race and 
stage at diagnosis, using available population-based registry data from 37 states.  This 
information is critical to prioritizing, planning and implementation of cancer control 
interventions.   
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Material and Methods 
Data Source and Variables 
Thirty-seven (37) state cancer registries affiliated with the National Program of Cancer 
Registries (NPCR) or the Surveillance, Epidemiology and End Results (SEER) Programs that 
participated in the CONCORD-2 study, (12) covering approximately 80% of the US population, 
agreed to the inclusion of their data in these analyses.  We analyzed individual tumor records for 
126,261 adults (aged 15-99 years) who were diagnosed with cancer of the liver and intrahepatic 
bile ducts (ICD-O-3 codes C22.0-C22.1) (13) during 2001-2009 and followed up through 
December 31, 2009. We included the first primary, invasive cancer of the liver, regardless of 
whether an individual had a previous cancer.  If an individual was diagnosed with two or more 
cancers of the liver during 2001 through 2009, only the first was considered in the survival 
analysis.   
 
We grouped patients by year of diagnosis into two calendar periods (2001-2003 and 2004-2009) 
to reflect changes in the methods used by US registries to collect SEER Summary Stage (SS) 
2000 at diagnosis (14).  During 2001-2003, most registries coded stage SS2000 directly from the 
medical records.  During 2004-2009, all registries derived SS2000 using the Collaborative 
Staging System (15).     
 
Survival analyses 
We analysed survival by state, race (all, black, white), SS2000 (local, regional, distant, 
unknown) and calendar period of diagnosis.  We estimated net survival up to 5 years after 
diagnosis, with 95% confidence intervals (CI), using the Pohar Perme estimator (16) of net 
survival. Net survival can be interpreted as the probability of survival up to a given time since 
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diagnosis, after controlling for other causes of death (background mortality). To control for the 
wide differences in background mortality between participating registries, we constructed life 
tables (17) of all-cause mortality in the general population of each state from the number of 
deaths and the population, by a single year of age, sex, calendar year, and where possible, by 
race (black, white), using a flexible Poisson model (18).   
 
We estimated net survival using the cohort approach for patients diagnosed in 2001-2003, since 
all patients had been followed up for at least five years by December 31, 2009.  We used the 
complete approach to estimate net survival for patients diagnosed from 2004-2009, because five 
years of follow-up data were not available for all patients.  Net survival was estimated for five 
age groups (15-44, 45-54, 55-64, 65-74, 75-99 years).  We obtained age-standardized survival 
estimates using the International Cancer Survival Standard (ICSS) weights (19).  If two or more 
of the five age-specific estimates could not be obtained, we present only the pooled, 
unstandardized survival estimates for all ages combined.  Unstandardized estimates are italicized 
in the tables.  Trends, geographic variations and differences in age-standardized survival by race 
are presented graphically in bar-charts and funnel plots (20).  Funnel plots of net survival for 
2001-2003 and 2004-2009 provide insight into the variability of cancer survival in the US by 
race and state and show how much a particular survival estimate deviates from the pooled 
estimate of US registries (horizontal line) given the precision of each estimate.  More details on 
data and methods are provided in the accompanying article (21). 
 
Results 
Liver cancer case distribution by race, state of residence, and stage at diagnosis by calendar 
period of diagnosis is reported in Table 1. In 2004-2009, liver cancer was mostly diagnosed at 
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localized stage (overall 41%), followed by regional (24%) and distant (18%). Stage at diagnosis 
varied slightly by race, with blacks being most often diagnosed at distant and regional stages 
(20% and 26%, respectively, compared to 17% and 24% in whites). However, state-specific 
analyses showed that patients with unknown stage at diagnosis ranged from 8% to 30%, which 
makes accurate comparisons across race at the national level difficult (Supplemental Table 1). 
Between the two calendar periods, there is indication of a shift towards earlier diagnosis of liver 
cancer, with an additional 8 percentage points in localized stage and 2 percentage points in 
regional stage, and a less than 1 percentage point increase in patients diagnosed with distant 
stage. Additionally, there was a substantial decline in the proportion of cases recorded with 
unknown stage at diagnosis, from 26% to 17%. 
 
Although the overall 5-year age-standardized net survival was low, 12% in 2001-2003 and 15% 
in 2004-2009, an improvement between the two calendar periods was observed (Figure 1). Of the 
35 states for which an age-standardized estimates were available, net survival increased between 
2001-2003 and 2004-2009 in 30 states, while only 5 states showed a decrease.  There was 
considerable variation by state in 2004-2009 in the 5-year survival, ranging from 8.1% in 
Wyoming to 20.9% in Florida (Supplemental Table 2). 
  
One-, 3-, and 5-year age-standardized net survival in 2004-2009 was 38%, 21%, 15%, 
respectively (Table 2). For each of the three time points, blacks showed lower age-standardized 
net survival than whites for all states combined.  The difference was most pronounced in the first 
year after diagnosis, suggesting that blacks have a lower survival in the short term in addition to 
lower survival at five years since diagnosis. Only four states showed considerable in-state racial 
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disparities, all with a survival disadvantage for blacks compared to whites. There was, however, 
a 5-year survival improvement for both races from 2001-2003 to 2004-2009, 2.6 percentage 
point increase for whites, and 2.3 percentage points for blacks. Five-year age-standardized net 
survival was 14.3% for whites and 11.4% for blacks. Overall 5-year survival for all races 
combined was 14.8%, higher than both blacks and whites. 
 
Five-year age-standardized net survival by stage (Table 3) for 2004-2009 was uniformly low at 
26%, 10% and 4% for localized, regional and distant stage, respectively. For localized stage, 
increases in survival were observed between 2001-2003 and 2004-2009 with a 2.8 percentage 
points for all races, 2.4 percentage points for whites and 5.0 percentage points for blacks. For 
regional and distant stages, smaller increases were observed, except that for blacks diagnosed 
with regional stage, for whom there was a decline in survival of 1 percentage point. While 5-year 
net survival was low in all states, there was considerable variation by stage and state 
(Supplemental Table 3). 
 
Figure 2 shows funnel plots of net survival for 2001-2003 and 2004-2009, to obtain further 
insight into the variability of liver survival in the US, by race and state.  Although survival for 
liver cancer was generally low in all states in both calendar periods, survival for black patients 
was lower than survival for white patients, and in most states it was lower than the pooled U.S. 
value. 
Discussion  
This study reports the most comprehensive comparison of trends in the United States in 5-year 
survival for liver cancer, using recent population-based data. The 5-year age-standardized net 
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survival for liver cancer reported in this analysis was low (15%) for the most recent period, but 
slightly higher than in 2001-2003 (12%). This slight increase may be partially explained by the 
increased proportion of patients diagnosed at localized stage who showed improved survival in 
the most recent years. Five-year survival in the US is slightly lower but still closely aligned with 
the 5-year survival estimates of Canada (17.7% [16.8-18.7%], 2005-2009) and slightly higher 
than survival in the United Kingdom (9.3% [8.7-9.9%], 2005-2009) (12). This study noted some 
variations in survival by state, race, and sex.  Whites had higher survival than blacks in both 
calendar periods.  Additionally, white women showed a survival rate that was 2.5 percentage 
points higher than white men, and black women showed a survival rate that was 5.5 percentage 
points higher than black men.  While our findings report a survival advantage for women, this is 
in contrast to those reported for Europe in the late 1990s (22). Micheli and colleagues reported 
an advantage for women for 11 of the 26 cancer sites; this advantage was not reported for liver 
cancer.  This difference may reflect a difference in US and European populations. Regardless of 
state, variations in liver cancer survival by race and gender are unknown, liver cancer is 
uniformly fatal across all populations.  Early diagnosis for liver cancer is challenging, since 
many of the symptoms associated with this disease do not present until later stages. In addition, 
due to the location of the liver beneath the rib cage, liver tumors are difficult to detect. 
 
This study suggests there is some improvement in liver cancer survival. Advances in treatment 
strategies likely contributed to this improvement.  Surgical resection, liver transplantation, and 
ablation are associated with best long-term survival. Surgical resection is usually performed in 
patients with localized HCC and sufficient preserved liver function. Liver transplantation is the 
best option for patients with decompensated cirrhosis and a solitary lesion (<5 cm) or early 
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multifocal disease (≤3 lesions, ≤3 cm in diameter) (23). When liver resection or transplantation is 
feasible, ablation may be used, particularly for patients with early-stage HCC that is centrally 
located in the liver.  Disparities in access to and receipt of appropriate surgical care may play an 
essential role for the racial differences we observed in liver cancer survival.  Studies have shown 
that African Americans and Asians with localized HCC were significantly less likely to receive a 
transplant compared to their white counterpart (24). In addition, African American patients were 
found to be younger and have a more advanced stage of disease than white patients, and were 
also more likely to die while waiting for a transplant (25). However, survival disparities by race 
may not be explained by differences in care only.  Artinyan and colleagues reported that racial 
differences in survival remained significant among patients who received liver transplantation 
(26).  
 
Clinical Implications 
To improve liver cancer survival, adherence to evidence-based treatment protocols among all 
populations, as well as other factors including biologic factors, response to therapy, patient 
comorbidities, post-treatment follow-up and care, and tumor recurrence all need to be 
considered.  Increased recruitment of non-white populations to liver cancer clinical trials may 
help alleviate racial differences in survival and improve the understanding of race-based 
differences in cancer biology (27).  HBV or HCV can cause persistent active hepatitis and 
hepatic fibrosis, which lead to the development of HCC and also has major impact on the 
prognosis of patients with HCC by affecting the rate of recurrence after surgery (28-30). 
Interferon therapy has shown to be beneficial for patients with hepatitis virus-associated HCC 
and can improve their outcome after curative resection (31).   
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Cancer Control Implications  
Given that most liver cancers are preventable (CDC), cancer control efforts and resources that 
support preventing infection and promoting viral hepatitis services should be prioritized (32-33).  
Approximately 22% of HCC among those aged 65 years or older in the United States is 
attributed to HCV, (10) and an estimated 1.6 million persons will be eligible for HCV treatment 
by 2020 (34). Antiviral therapies for hepatitis B and hepatitis C can help prevent liver cancer, 
and also result in decreased neuroinflammation in the liver and over time cause reversal of 
fibrosis, which also leads to decreased HCC risk (35).  In 2012, the CDC recommended one-time 
HCV testing for persons born during 1945–1965 (aged 47–67 years in 2012) (36). The following 
year, the US Preventive Services Task Force issued similar recommendations (37). According to 
the National Academies of Science, Engineering, and Medicine (38), limited public and provider 
awareness, as well as limited public resource allocation are the primary underlying causes of 
high rates of chronic hepatitis B and C in the United States (38).  In the U.S., Asians have the 
highest incidence of HBV (39). However, for other populations (non-Asians), the incidence of 
HBV is not as much a concern as the incidence of HCV, which assumes a bigger role in the 
etiology of liver cancer (40). For the latter group, the patterns among immigrants are consistent 
and gender specific, with a higher incidence and mortality for males when coming to the U.S., 
but females having stabilized or slightly decreased rates. This has been shown for different 
populations (Hispanics and non-Hispanic Blacks) (41-43). CDC’s National Comprehensive 
Cancer Control Program (NCCCP) is currently working on the development and implementation 
of an action plan that would facilitate greater implementation and uptake of strategies and 
interventions to address liver cancer within selected pilot programs that have a high liver cancer 
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burden.  The action plan will contain interventions specific to increasing support for vaccine-
based strategies to eliminate HBV transmission, and development of prevention and health 
services that include screening for HBV and HCV infections linked to appropriate medical 
management and care (in alignment with recommendations), community education about HBV 
and HCV, and the improvement of viral hepatitis surveillance.  Improved surveillance for HBV 
and patients with HCV-related cirrhosis has the potential to result in the detection of more 
cancers at a localized stage when surgery may be possible and more beneficial (44).   
 
Strength and Limitations 
This analysis has several strengths, including that it includes a very large number of US states, 
making it the most geographically-comprehensive survival study to our knowledge.  Also, the 
sophisticated and complex methodology takes into account the competing risks of death that are 
higher for elderly than for younger cancer patients.  Finally, more than 70% of all cases included 
in this analysis were morphologically verified, contributing to the high quality of the data used.   
A limitation of our analysis is that some stage and race categories had missing data or small 
numbers. The small black population in some states precluded the construction of life tables for 
the black population in these states; therefore the state-specific life tables for all races combined 
were used instead.   Additionally, data on populations with a higher burden of liver cancer, 
including Asian/Pacific Islanders and Hispanics, were not collected or analyzed in this study.   
 
Conclusions 
Cancer incidence in the United States is expected to increase greatly due to demographic changes 
such as an aging population and a larger proportion of individuals from racial/ethnic groups; it is 
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estimated that liver cancer will rank the second highest of increase (59%) between 2010 through 
2030 among all cancer sites (45).  This analysis suggests some progress in five-year survival for 
liver cancer in the U.S.; however, there is still much more work that needs to be done in order to 
reduce the burden of this cancer.  Improvements in surveillance, prevention and detection of 
HBV and HCV infection may have the greatest potential of leading to earlier detection resulting 
in increased survival.   
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Figures and Tables  
Figure 1.          Liver cancer: 5-year age-standardized net survival (%) for adults (15-99 years) 
diagnosed during 2001-2003 and 2004-2009, and absolute change (%): states grouped by U.S. 
Census Region. 
Note:  Data from 37 statewide cancer registries (covering 80.6% of the population) are ranked 
within U.S. Census Region by the survival estimate for 2004-2009. Dark colors denote states 
affiliated with the National Program of Cancer Registries (NPCR); pale colors denote states 
affiliated with the Surveillance, Epidemiology and End Results (SEER) Program;  *  denotes 
states affiliated with both federal surveillance programs.  Change (%) not plotted if a survival 
estimate was not available for one calendar period or one or more estimates was not age-
standardized.  
Figure 2. Liver cancer: 5-year age-standardized net survival (%) for adults (15-99 years), by 
state, race and calendar period of diagnosis.  
Note: the pooled (US) survival estimate for each calendar period is shown by the horizontal 
(solid) line with corresponding 95.0% and 99.8% control limits (dotted lines). 
 
Supplemental Table 1. Liver cancer: number of cases for adults (15-99 years) diagnosed during 
2001-2003 and 2004-2009 and distribution (%) by SEER Summary Stage 2000 at diagnosis, race 
and calendar period of diagnosis.  
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program. Information on stage was not available for two states 
(Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009.  This is 
the same information that appears in Table 1. 
 
Supplemental Table 2.  Liver cancer: 1-, 3- and 5-years age-standardized net survival (%) for 
adults (15-99 years) diagnosed during 2001-2003 and 2004-2009, by race and calendar period 
of diagnosis. 
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program. Unstandardized estimates are italicized.  
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Supplemental Table 3.  Liver cancer: 5-year age-standardized net survival (%) for adults (15-99 
years) diagnosed during 2001-2003 and 2004-2009, by SEER Summary Stage 2000 at 
diagnosis, race and calendar period.  
Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, 
Epidemiology, and End Results program. Information on stage was not available for two states 
(Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009.    
Unstandardized estimates are italicized. 
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Table 1.  Liver cancer: number of cases for males and females (15-99 years) diagnosed 2001-2009 and distribution (%) by SEER 
Summary Stage 2000 (SS2000) at diagnosis, by race and calendar period of diagnosis. 
 2001-2003 2004-2009 
SS2000  All races White Black All races White Black 
No. of 
patients 
 33,690 25,500 4,225 
92,571 
69,374 13,002 
Localized (%) 33.4 33.2 30.4 41.0 40.9 38.8 
Regional  (%) 22.4 21.6 23.6 24.4 23.8 25.9 
Distant (%) 18.4 18.2 20.4 17.6 17.4 19.8 
Unknown (%) 25.8 27.0 25.6 17.0 17.8 15.5 
 
Table 2.  Liver cancer: age-standardized net survival (%) at 1-, 3- and 5-years for females (15-99 years) diagnosed 2001-2009, by race 
and calendar period of diagnosis. 
 2001-2003 2004-2009 
 All races White Black All races White Black 
Yea
rs 
NS 
(%
)  
95% CI NS 
(%
) 
95% CI NS 
(%
) 
95% CI NS 
(%
) 
95% CI NS 
(%
) 
95% CI N
S 
(
%
) 
95% CI 
1 31.
8 
31.
3 
- 32
.3 
31.
7 
31.
1 
- 32.
3 
27.
3 
25.
8 
- 28.
9 
38.
2 
37
.8 
- 38
.5 
38.
0 
37
.6 
- 38
.4 
32
.9 
31
.9 
- 33
.9 
3 16.
2 
15.
8 
- 16
.7 
15.
7 
15.
3 
- 16.
2 
13.
2 
11.
9 
- 14.
4 
20.
5 
20
.1 
- 20
.8 
19.
9 
19
.5 
- 20
.3 
16
.5 
15
.5 
- 17
.5 
5 12.
2 
11.
8 
- 12
.5 
11.
7 
11.
3 
- 12.
1 
9.1 8.0 - 10.
2 
14.
8 
14
.4 
- 15
.2 
14.
3 
13
.8 
- 14
.8 
11
.4 
10
.3 
- 12
.5 
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Table 3.  Liver cancer: 5-year age-standardized net survival (%) for females (15-99 years) diagnosed 2001-2009, by SEER Summary 
Stage (SS2000) at diagnosis, race and calendar period of diagnosis. 
 2001-2003 2004-2009 
 All races White Black All races White Black 
SS200
0 
N
S 
(
%
)  
 NS 
(%
)  
 N
S 
(
%
)  
 NS 
(%
)  
 N
S 
(
%
)  
 N
S 
(
%
)  
 
All 
stages 
12
.2 
11
.8 
- 12.5 11.
7 
11
.3 
- 12.1 9.
1 
8.
0 
- 10.2 14.
8 
14
.4 
- 15.2 14
.3 
13
.8 
- 14
.8 
11
.4 
10
.3 
- 12
.5 
Locali
zed 
22
.9 
22
.1 
- 23.8 22.
4 
21
.4 
- 23.4 15
.8 
13
.3 
- 18.2 25.
7 
24
.9 
- 26.5 24
.8 
23
.9 
- 25
.7 
20
.8 
18
.4 
- 23
.3 
Regio
nal 
8.
3 
7.
6 
- 9.0 7.6 6.
8 
- 8.4 8.
3 
6.
3 
- 10.4 9.5 8.
8 
- 10.2 9.
2 
8.
4 
- 9.
9 
7.
1 
5.
4 
- 8.
9 
Distan
t 
2.
8 
2.
4 
- 3.3 2.4 2.
0 
- 2.9 2.
5 
1.
2 
- 3.8 3.5 3.
0 
- 4.0 2.
9 
2.
3 
- 3.
4 
3.
8 
2.
6 
- 5.
1 
Unkno
wn 
8.
2 
7.
6 
- 8.9 7.9 7.
2 
- 8.7 7.
0 
5.
3 
- 8.8 8.9 8.
2 
- 9.6 9.
0 
8.
1 
- 9.
8 
6.
2 
4.
6 
- 7.
8 
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Stage All races White Black All races White Black
UNITED STATES
No. of patients 33,690 25,500 4,225 92,571 69,374 13,002
Localized (%) 33.4 33.2 30.4 41.0 40.9 38.8
Regional (%) 22.4 21.6 23.6 24.4 23.8 25.9
Distant (%) 18.4 18.2 20.4 17.6 17.4 19.8
Unknown (%) 25.8 27.0 25.6 17.0 17.8 15.5
NORTHEAST
New England
Connecticut No. of patients 492 421 53 1,411 1,170 164
(SEER) Localized (%) 36.6 36.8 35.8 41.2 40.8 42.1
Regional (%) 17.5 16.6 22.6 24.9 23.9 32.3
Distant (%) 19.5 19.5 17.0 18.9 19.4 15.9
Unknown (%) 26.4 27.1 24.5 15.0 15.9 9.8
Massachusetts No. of patients 998 827 75 2,741 2,299 178
(NPCR) Localized (%) 34.4 34.0 28.0 40.9 41.0 33.7
Regional (%) 25.4 24.9 32.0 26.4 26.1 32.6
Distant (%) 15.8 16.2 14.7 16.7 16.8 15.7
Unknown (%) 24.4 24.9 25.3 16.0 16.1 18.0
New Hampshire No. of patients 133 118 - 355 332 -
(NPCR) Localized (%) 24.8 24.6 66.7 35.5 35.5 50.0
Regional (%) 24.1 21.2 33.3 27.9 28.6 50.0
Distant (%) 16.5 17.8 0.0 17.2 17.8 0.0
Unknown (%) 34.6 36.4 0.0 19.4 18.1 0.0
Rhode Island No. of patients 176 161 10 409 353 32
(NPCR) Localized (%) 29.5 29.8 30.0 - - -
Regional (%) 29.0 28.6 40.0 - - -
Distant (%) 15.3 13.7 30.0 - - -
Unknown (%) 26.1 28.0 0.0 - - -
Mid Atlantic
New Jersey No. of patients 1,421 1,093 199 3,339 2,587 488
(NPCR/SEER) Localized (%) 30.6 29.1 33.2 41.6 41.0 40.8
Regional (%) 19.7 19.7 21.1 21.2 21.3 20.7
Distant (%) 20.1 20.4 21.6 16.4 16.2 18.0
Unknown (%) 29.6 30.8 24.1 20.8 21.5 20.5
New York No. of patients 3,465 2,458 578 8,877 6,052 1,670
(NPCR) Localized (%) 28.1 27.8 23.9 41.4 40.4 39.2
Regional (%) 21.0 20.5 24.2 23.9 24.0 25.5
Distant (%) 17.7 17.4 19.7 18.6 18.7 21.0
Unknown (%) 33.2 34.3 32.2 16.1 16.9 14.4
Pennsylvania No. of patients 2,004 1,569 322 5,026 3,957 821
(NPCR) Localized (%) 31.2 31.2 29.2 42.6 41.7 43.7
Regional (%) 24.5 25.7 20.8 26.5 26.3 28.7
Distant (%) 20.5 20.0 23.6 18.2 18.7 16.9
Unknown (%) 23.8 23.0 26.4 12.8 13.3 10.6
SOUTH
South Atlantic
Delaware No. of patients 106 87 16 310 218 81
(NPCR) Localized (%) 41.5 41.4 43.8 45.8 47.2 40.7
Regional (%) 21.7 17.2 43.8 26.1 25.7 27.2
Distant (%) 16.0 17.2 12.5 19.7 19.3 22.2
Unknown (%) 20.8 24.1 0.0 8.4 7.8 9.9
Florida No. of patients 2,721 2,337 276 7,339 6,063 946
(NPCR) Localized (%) 29.1 29.3 26.4 38.9 39.6 33.4
Regional (%) 19.8 19.3 25.4 23.3 23.0 26.6
Distant (%) 20.3 20.1 22.8 16.5 16.0 20.0
Unknown (%) 30.8 31.4 25.4 21.3 21.3 20.0
Georgia No. of patients 813 540 217 2,698 1,798 764
(NPCR/SEER) Localized (%) 35.9 36.3 33.6 43.7 44.4 42.3
Regional (%) 21.5 20.4 24.0 25.8 25.0 27.7
Distant (%) 19.8 20.6 19.4 18.9 17.7 21.9
Unknown (%) 22.8 22.8 23.0 11.6 12.9 8.1
2001-2003 2004-2009
Table 1 – Stage distribution by state and race – Liver Page 1 of 4 Produced 29 July 2016
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2001-2003 2004-2009
Maryland No. of patients 657 411 192 1,524 901 517
(NPCR) Localized (%) - - - - - -
Regional (%) - - - - - -
Distant (%) - - - - - -
Unknown (%) - - - - - -
North Carolina No. of patients 934 695 197 2,873 2,094 631
(NPCR) Localized (%) 38.1 41.3 28.9 41.8 41.8 40.9
Regional (%) 21.1 20.4 21.8 25.5 25.6 26.0
Distant (%) 17.8 16.3 21.8 17.9 17.3 18.9
Unknown (%) 23.0 22.0 27.4 14.8 15.3 14.3
South Carolina No. of patients 485 352 118 1,339 951 347
(NPCR) Localized (%) 36.9 38.9 30.5 40.0 40.9 37.5
Regional (%) 17.5 18.2 16.1 22.3 22.0 23.1
Distant (%) 15.5 15.1 16.1 17.8 17.4 19.9
Unknown (%) 30.1 27.8 37.3 19.9 19.8 19.6
West Virginia No. of patients 230 220 - 562 531 27
(NPCR) Localized (%) 25.7 25.9 25.0 35.6 35.6 33.3
Regional (%) 16.1 16.4 0.0 21.4 21.7 14.8
Distant (%) 19.1 19.1 12.5 15.1 14.5 29.6
Unknown (%) 39.1 38.6 62.5 27.9 28.2 22.2
East South Central
Alabama No. of patients 514 381 119 1,408 1,068 317
(NPCR) Localized (%) 30.2 29.7 30.3 43.4 44.7 38.8
Regional (%) 21.6 21.5 20.2 20.7 19.9 23.7
Distant (%) 18.7 19.7 16.8 17.0 16.0 19.9
Unknown (%) 29.6 29.1 32.8 18.8 19.4 17.7
Kentucky No. of patients 466 418 41 1,353 1,207 129
(NPCR/SEER) Localized (%) 35.8 35.4 36.6 43.7 42.8 50.4
Regional (%) 21.2 20.6 31.7 23.7 24.3 17.8
Distant (%) 17.2 17.7 14.6 18.6 17.9 24.8
Unknown (%) 25.8 26.3 17.1 14.1 15.0 7.0
Mississippi No. of patients 128 91 28 899 622 251
(NPCR) Localized (%) 35.9 37.4 35.7 38.2 41.0 32.3
Regional (%) 20.3 19.8 14.3 29.0 26.5 34.3
Distant (%) 22.7 24.2 21.4 20.2 19.3 21.9
Unknown (%) 21.1 18.7 28.6 12.6 13.2 11.6
Tennessee No. of patients 177 149 22 1,805 1,417 334
(NPCR) Localized (%) 40.7 42.3 36.4 46.1 46.4 42.8
Regional (%) 22.6 24.2 9.1 22.7 22.4 23.1
Distant (%) 19.2 16.1 36.4 16.8 16.7 19.8
Unknown (%) 17.5 17.4 18.2 14.4 14.5 14.4
West South Central
Louisiana No. of patients 694 464 211 1,739 1,066 609
(NPCR/SEER) Localized (%) 41.2 43.8 37.0 49.7 50.3 47.5
Regional (%) 24.9 24.6 25.1 23.1 22.1 25.0
Distant (%) 18.0 15.5 22.7 18.0 17.4 19.2
Unknown (%) 15.9 16.2 15.2 9.3 10.2 8.4
Oklahoma No. of patients 425 319 37 1,280 979 85
(NPCR) Localized (%) 28.7 28.5 18.9 37.3 39.0 31.8
Regional (%) 15.3 14.4 16.2 20.0 19.0 24.7
Distant (%) 21.9 23.2 24.3 19.8 19.1 24.7
Unknown (%) 34.1 33.9 40.5 23.0 22.9 18.8
Texas No. of patients 3,543 2,944 405 10,265 8,253 1,422
(NPCR) Localized (%) 34.1 34.2 33.1 41.5 42.7 35.6
Regional (%) 17.3 16.5 22.2 20.7 19.7 26.1
Distant (%) 17.6 17.4 20.0 17.2 16.7 19.9
Unknown (%) 31.0 31.8 24.7 20.6 20.9 18.4
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MIDWEST
East North Central
Michigan No. of patients 1,412 1,072 278 3,485 2,559 755
(NPCR/SEER) Localized (%) 30.5 30.1 31.3 35.0 35.0 34.8
Regional (%) 19.6 18.9 21.9 16.2 16.1 15.8
Distant (%) 20.0 19.1 24.8 19.3 18.8 21.5
Unknown (%) 30.0 31.8 21.9 29.5 30.1 27.9
Ohio No. of patients 1,301 1,036 215 3,476 2,735 634
(NPCR) Localized (%) 28.5 29.0 26.5 35.5 34.8 36.1
Regional (%) 17.8 18.0 17.2 21.9 20.7 26.7
Distant (%) 15.5 15.6 14.9 15.0 15.1 14.8
Unknown (%) 38.1 37.5 41.4 27.6 29.4 22.4
Wisconsin No. of patients 660 587 45 1,661 1,370 158
(NPCR) Localized (%) - - - - - -
Regional (%) - - - - - -
Distant (%) - - - - - -
Unknown (%) - - - - - -
West North Central
Iowa No. of patients 295 276 - 861 795 28
(SEER) Localized (%) 30.2 30.1 40.0 36.4 37.0 32.1
Regional (%) 28.8 29.7 20.0 30.0 29.1 42.9
Distant (%) 20.3 19.9 20.0 20.6 20.0 25.0
Unknown (%) 20.7 20.3 20.0 13.1 14.0 0.0
Nebraska No. of patients 243 217 11 595 513 44
(NPCR) Localized (%) 33.3 32.7 54.5 34.6 35.3 29.5
Regional (%) 22.2 21.7 18.2 31.1 31.0 31.8
Distant (%) 15.6 14.7 18.2 17.8 16.6 25.0
Unknown (%) 28.8 30.9 9.1 16.5 17.2 13.6
WEST
Mountain
Colorado No. of patients 521 436 32 1,442 1,255 74
(NPCR) Localized (%) 37.0 37.8 25.0 41.9 41.5 33.8
Regional (%) 21.9 20.9 34.4 25.0 24.5 27.0
Distant (%) 20.2 19.5 25.0 19.2 19.7 25.7
Unknown (%) 20.9 21.8 15.6 13.9 14.3 13.5
Idaho No. of patients 92 88 - 332 316 -
(NPCR) Localized (%) 33.7 33.0 - 38.0 38.0 -
Regional (%) 29.3 30.7 - 26.2 26.9 -
Distant (%) 18.5 17.0 - 21.1 21.5 -
Unknown (%) 18.5 19.3 - 14.8 13.6 -
Montana No. of patients 76 67 - 232 191 -
(NPCR) Localized (%) 25.0 23.9 100.0 40.5 42.4 -
Regional (%) 23.7 23.9 0.0 31.5 29.8 -
Distant (%) 10.5 11.9 0.0 17.2 17.8 -
Unknown (%) 40.8 40.3 0.0 10.8 9.9 -
New Mexico No. of patients 332 293 - 911 783 13
(SEER) Localized (%) 42.8 43.3 33.3 42.7 42.5 38.5
Regional (%) 16.3 14.7 0.0 16.9 17.2 15.4
Distant (%) 19.3 19.8 33.3 18.8 19.2 30.8
Unknown (%) 21.7 22.2 33.3 21.6 21.1 15.4
Utah No. of patients 139 117 - 456 405 11
(SEER) Localized (%) 46.0 46.2 - 44.5 45.4 45.5
Regional (%) 24.5 21.4 - 30.9 30.1 18.2
Distant (%) 15.1 17.1 - 14.5 14.3 18.2
Unknown (%) 14.4 15.4 - 10.1 10.1 18.2
Wyoming No. of patients 41 38 - 131 125 -
(NPCR) Localized (%) 17.1 18.4 0.0 43.5 44.0 -
Regional (%) 17.1 18.4 0.0 22.9 23.2 -
Distant (%) 14.6 15.8 0.0 13.7 12.8 -
Unknown (%) 51.2 47.4 100.0 19.8 20.0 -
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2001-2003 2004-2009
Pacific
Alaska No. of patients 100 62 - 238 141 16
(NPCR) Localized (%) 28.0 22.6 50.0 43.7 41.8 56.3
Regional (%) 22.0 21.0 25.0 23.9 23.4 18.8
Distant (%) 18.0 16.1 0.0 16.4 14.9 6.3
Unknown (%) 32.0 40.3 25.0 16.0 19.9 18.8
California No. of patients 6,206 4,044 456 16,772 11,251 1,285
(NPCR/SEER) Localized (%) 38.2 38.0 32.9 43.1 42.7 38.7
Regional (%) 27.4 26.1 32.2 28.0 27.4 31.1
Distant (%) 18.1 17.8 21.3 17.5 17.7 21.0
Unknown (%) 16.3 18.1 13.6 11.5 12.2 9.2
Hawaii No. of patients 364 49 - 818 185 11
(SEER) Localized (%) 40.7 38.8 100.0 41.7 36.2 18.2
Regional (%) 34.3 36.7 0.0 27.9 28.1 27.3
Distant (%) 19.8 16.3 0.0 18.2 20.0 45.5
Unknown (%) 5.2 8.2 0.0 12.2 15.7 9.1
Oregon No. of patients 430 362 - 1,440 1,219 39
(NPCR) Localized (%) 24.9 24.9 33.3 36.6 36.3 35.9
Regional (%) 26.0 24.3 33.3 29.7 28.9 25.6
Distant (%) 18.6 19.1 11.1 18.4 18.5 15.4
Unknown (%) 30.5 31.8 22.2 15.3 16.3 23.1
Washington No. of patients 896 701 34 2,169 1,613 119
(NPCR/SEER) Localized (%) 37.9 37.1 41.2 38.7 36.9 48.7
Regional (%) 33.4 31.7 44.1 31.0 31.1 31.9
Distant (%) 14.4 14.8 11.8 18.9 19.4 16.8
Unknown (%) 14.3 16.4 2.9 11.3 12.6 2.5
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Years NS NS NS NS NS NS 
UNITED STATES
1 31.8 31.3 - 32.3 31.7 31.1 - 32.3 27.3 25.8 - 28.9 38.2 37.8 - 38.5 38.0 37.6 - 38.4 32.9 31.9 - 33.9
3 16.2 15.8 - 16.7 15.7 15.3 - 16.2 13.2 11.9 - 14.4 20.5 20.1 - 20.8 19.9 19.5 - 20.3 16.5 15.5 - 17.5
5 12.2 11.8 - 12.5 11.7 11.3 - 12.1 9.1 8.0 - 10.2 14.8 14.4 - 15.2 14.3 13.8 - 14.8 11.4 10.3 - 12.5
NORTHEAST
New England
Connecticut 1 35.4 31.0 - 39.8 36.6 31.8 - 41.4 30.5 18.1 - 42.9 42.8 40.0 - 45.6 42.7 39.7 - 45.8 43.9 35.0 - 52.9
(SEER) 3 17.4 13.9 - 20.9 18.3 14.4 - 22.3 17.3 6.9 - 27.7 22.3 19.6 - 25.1 22.7 19.6 - 25.8 20.4 12.2 - 28.7
5 12.4 9.2 - 15.5 12.8 9.4 - 16.2 13.5 3.4 - 23.5 14.5 11.4 - 17.7 14.9 11.4 - 18.5 16.1 7.7 - 24.4
Massachusetts 1 36.4 33.3 - 39.4 35.3 32.0 - 38.7 34.2 23.3 - 45.0 43.0 40.9 - 45.0 41.7 39.5 - 44.0 41.8 33.1 - 50.5
(NPCR) 3 17.9 15.4 - 20.3 16.1 13.5 - 18.7 16.8 8.2 - 25.3 24.2 22.1 - 26.4 21.8 19.5 - 24.1 27.5 18.2 - 36.8
5 14.0 11.7 - 16.4 13.1 10.6 - 15.5 10.3 3.4 - 17.2 15.6 13.0 - 18.2 13.6 10.9 - 16.4 20.3 13.0 - 27.6
New Hampshire 1 32.4 24.9 - 39.8 29.6 21.9 - 37.3 - 34.9 29.6 - 40.2 35.5 30.1 - 41.0 -
(NPCR) 3 16.0 10.1 - 21.8 14.5 8.7 - 20.4 - 15.7 11.2 - 20.3 16.2 11.4 - 21.0 -
5 12.2 6.9 - 17.5 10.9 5.7 - 16.1 - 12.5 8.6 - 16.4 12.4 8.3 - 16.4 -
Rhode Island 1 30.3 23.6 - 37.0 29.6 23.1 - 36.2 40.7 12.4 - 69.0 36.1 30.9 - 41.2 34.9 29.7 - 40.0 51.6 34.0 - 69.3
(NPCR) 3 16.9 11.3 - 22.5 16.4 10.9 - 21.9 20.6 0.0 - 42.9 16.8 12.3 - 21.3 14.4 10.2 - 18.7 28.5 10.6 - 46.4
5 12.8 7.7 - 17.8 11.7 6.8 - 16.6 20.6 0.0 - 42.9 10.7 6.8 - 14.7 9.9 6.1 - 13.6 14.3 0.0 - 31.3
Mid Atlantic
New Jersey 1 33.6 31.1 - 36.1 32.7 29.9 - 35.5 29.9 23.3 - 36.6 41.1 39.3 - 43.0 42.5 40.5 - 44.6 33.3 28.2 - 38.5
(NPCR/SEER) 3 17.9 15.8 - 20.0 17.6 15.2 - 20.0 10.3 6.3 - 14.3 20.2 18.5 - 22.0 20.8 18.8 - 22.8 15.0 10.1 - 19.9
5 12.6 10.7 - 14.4 12.3 10.2 - 14.4 6.9 3.8 - 10.0 14.8 12.8 - 16.8 15.4 13.1 - 17.6 8.8 4.2 - 13.4
New York 1 36.5 34.9 - 38.2 35.3 33.3 - 37.2 32.1 27.8 - 36.4 43.7 42.6 - 44.8 42.4 41.0 - 43.7 40.3 37.5 - 43.1
(NPCR) 3 20.8 19.4 - 22.2 19.0 17.3 - 20.6 17.5 13.9 - 21.0 25.9 24.8 - 27.1 23.8 22.4 - 25.1 23.2 20.4 - 26.0
5 16.8 15.5 - 18.2 14.6 13.1 - 16.2 13.1 9.9 - 16.4 20.4 19.1 - 21.7 18.2 16.6 - 19.8 16.5 13.5 - 19.5
Pennsylvania 1 32.1 29.9 - 34.2 32.7 30.2 - 35.1 29.4 23.7 - 35.1 39.8 38.3 - 41.3 39.5 37.8 - 41.2 39.0 34.6 - 43.4
(NPCR) 3 17.0 15.2 - 18.7 17.0 14.9 - 19.0 13.3 9.0 - 17.6 20.1 18.7 - 21.6 20.0 18.4 - 21.7 14.3 11.2 - 17.5
5 12.3 10.7 - 13.9 12.2 10.4 - 14.0 7.9 4.8 - 11.1 15.1 13.5 - 16.8 14.7 12.8 - 16.5 13.4 10.2 - 16.5
SOUTH
South Atlantic
Delaware 1 35.2 26.4 - 44.0 35.5 26.0 - 45.0 38.0 15.0 - 61.0 38.7 32.5 - 44.8 40.5 33.6 - 47.4 41.2 30.1 - 52.2
(NPCR) 3 19.6 12.3 - 26.8 20.8 12.8 - 28.7 13.5 0.0 - 28.5 23.1 16.9 - 29.2 21.9 15.2 - 28.7 30.6 19.4 - 41.8
5 12.1 5.8 - 18.3 13.3 6.3 - 20.3 7.6 0.0 - 18.9 14.5 8.0 - 21.1 13.5 7.1 - 19.9 16.8 3.0 - 30.5
Florida 1 33.8 32.0 - 35.6 34.6 32.6 - 36.6 26.2 20.4 - 32.0 41.3 40.1 - 42.5 42.1 40.7 - 43.5 33.1 29.4 - 36.7
(NPCR) 3 18.5 16.9 - 20.0 18.4 16.7 - 20.1 17.3 12.0 - 22.6 24.8 23.5 - 26.0 25.1 23.7 - 26.5 18.9 15.5 - 22.3
5 14.8 13.3 - 16.2 14.5 12.9 - 16.1 14.3 9.0 - 19.6 20.9 19.3 - 22.4 20.8 19.1 - 22.6 17.4 13.7 - 21.1
Georgia 1 25.6 22.5 - 28.8 25.7 21.9 - 29.5 23.7 17.5 - 29.9 35.0 32.9 - 37.1 36.1 33.6 - 38.5 31.6 27.2 - 36.0
(NPCR/SEER) 3 11.4 9.1 - 13.7 11.7 8.9 - 14.5 8.9 4.8 - 12.9 17.7 15.8 - 19.7 18.5 16.1 - 20.8 15.6 11.5 - 19.8
5 7.6 5.6 - 9.6 8.2 5.7 - 10.6 4.5 1.7 - 7.2 12.5 10.4 - 14.6 13.3 10.8 - 15.7 10.9 6.3 - 15.4
Maryland 1 26.9 23.4 - 30.4 28.8 24.3 - 33.4 22.1 16.1 - 28.2 34.5 31.9 - 37.1 35.5 32.1 - 38.8 29.7 24.9 - 34.5
(NPCR) 3 13.7 10.9 - 16.5 12.6 9.3 - 15.9 13.7 8.5 - 18.8 16.9 14.5 - 19.4 17.0 14.0 - 19.9 12.4 8.5 - 16.2
5 10.7 8.1 - 13.3 9.7 6.7 - 12.7 10.8 6.1 - 15.5 13.4 10.8 - 16.0 13.5 10.6 - 16.5 8.9 5.0 - 12.7
North Carolina 1 25.0 22.2 - 27.8 26.8 23.4 - 30.1 16.8 11.7 - 21.8 35.4 33.4 - 37.4 36.9 34.5 - 39.2 28.6 23.9 - 33.3
(NPCR) 3 13.8 11.5 - 16.1 14.3 11.6 - 17.0 8.8 5.2 - 12.3 17.4 15.4 - 19.3 18.9 16.6 - 21.2 12.0 7.9 - 16.0
5 10.2 8.1 - 12.4 10.7 8.2 - 13.2 5.7 2.8 - 8.6 12.0 9.9 - 14.1 13.3 10.8 - 15.9 5.9 2.5 - 9.3
South Carolina 1 27.6 23.6 - 31.6 28.8 24.2 - 33.5 29.9 20.8 - 39.0 30.1 27.4 - 32.9 31.7 28.4 - 35.0 23.4 17.9 - 28.8
(NPCR) 3 14.5 11.2 - 17.7 15.4 11.6 - 19.2 16.0 8.1 - 23.8 13.3 10.7 - 15.9 15.7 12.5 - 18.8 6.8 3.4 - 10.3
5 10.0 7.2 - 12.7 11.6 8.2 - 15.1 6.7 2.2 - 11.1 10.4 7.7 - 13.1 11.9 8.5 - 15.2 6.5 2.5 - 10.4
West Virginia 1 23.5 17.9 - 29.1 23.8 18.1 - 29.5 - 30.1 26.0 - 34.3 30.2 25.8 - 34.5 31.7 12.8 - 50.7
(NPCR) 3 9.1 5.4 - 12.9 9.6 5.7 - 13.5 - 16.3 12.2 - 20.3 15.9 11.8 - 20.0 8.7 0.0 - 20.8
5 6.3 3.1 - 9.5 6.6 3.3 - 10.0 - 9.2 5.4 - 13.1 7.9 4.5 - 11.4 9.0 0.0 - 21.3
East South Central
Alabama 1 24.8 21.0 - 28.6 25.0 20.7 - 29.4 24.3 15.6 - 33.0 31.4 28.7 - 34.1 32.5 29.3 - 35.7 29.3 23.5 - 35.2
(NPCR) 3 11.5 8.6 - 14.4 10.6 7.5 - 13.7 12.8 6.1 - 19.4 16.5 13.9 - 19.0 18.9 15.9 - 21.8 11.9 7.0 - 16.8
5 8.3 5.6 - 10.9 7.3 4.5 - 10.0 7.8 3.3 - 12.3 9.8 7.3 - 12.3 11.4 8.2 - 14.6 4.5 1.4 - 7.7
Kentucky 1 30.6 26.3 - 34.9 30.4 25.9 - 34.9 35.2 20.7 - 49.6 32.5 29.8 - 35.2 32.6 29.8 - 35.5 36.6 27.7 - 45.5
(NPCR/SEER) 3 13.7 10.5 - 17.0 13.9 10.5 - 17.3 14.2 3.6 - 24.8 18.4 15.8 - 21.1 18.3 15.6 - 21.1 15.6 7.1 - 24.2
5 10.3 7.4 - 13.2 10.3 7.3 - 13.3 11.9 1.8 - 21.9 11.2 8.5 - 14.0 11.6 8.6 - 14.5 9.8 1.8 - 17.8
Mississippi 1 24.6 17.2 - 32.0 28.2 19.9 - 36.5 18.2 4.5 - 31.9 31.2 27.8 - 34.6 32.5 28.4 - 36.6 25.7 19.4 - 32.1
(NPCR) 3 13.8 7.8 - 19.9 16.9 9.7 - 24.1 3.7 0.0 - 9.3 16.1 12.9 - 19.2 17.3 13.5 - 21.0 16.8 10.5 - 23.1
5 7.1 2.6 - 11.6 8.0 2.8 - 13.2 3.7 0.0 - 9.3 11.3 8.0 - 14.6 13.5 9.6 - 17.4 8.6 3.6 - 13.5
Tennessee 1 26.9 20.7 - 33.2 28.0 21.4 - 34.6 23.2 6.5 - 40.0 35.1 32.5 - 37.7 35.0 32.1 - 37.8 32.3 25.9 - 38.8
(NPCR) 3 11.8 7.8 - 15.9 14.0 9.3 - 18.6 4.8 0.0 - 12.1 17.0 14.6 - 19.4 16.2 13.6 - 18.8 18.3 12.2 - 24.4
5 8.2 4.6 - 11.7 10.0 5.9 - 14.1 0.0 - 11.5 9.0 - 13.9 10.7 8.2 - 13.2 12.0 5.9 - 18.1
West South Central
Louisiana 1 26.4 23.1 - 29.8 29.5 25.3 - 33.6 21.7 15.6 - 27.7 32.6 30.1 - 35.1 34.9 31.7 - 38.1 27.8 23.4 - 32.3
(NPCR/SEER) 3 11.5 9.1 - 13.9 15.0 11.7 - 18.2 6.2 3.0 - 9.4 15.7 13.4 - 18.0 18.3 15.3 - 21.3 10.7 7.1 - 14.3
5 9.1 6.8 - 11.4 11.9 8.9 - 15.0 5.0 2.1 - 7.9 9.3 7.1 - 11.6 11.1 8.1 - 14.0 6.8 3.4 - 10.2
95% CI95% CI 95% CI 95% CI 95% CI 95% CI
2001-2003 2004-2009
All races White Black All races White Black
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Years NS NS NS NS NS NS 95% CI95% CI 95% CI 95% CI 95% CI 95% CI
2001-2003 2004-2009
All races White Black All races White Black
Oklahoma 1 26.3 22.1 - 30.6 27.4 22.4 - 32.3 27.7 13.5 - 42.0 31.5 28.7 - 34.3 32.6 29.3 - 35.8 36.1 24.7 - 47.6
(NPCR) 3 11.9 8.7 - 15.1 11.3 7.6 - 15.0 18.2 5.8 - 30.5 16.2 13.6 - 18.9 15.7 12.7 - 18.6 23.3 12.9 - 33.7
5 8.1 5.4 - 10.8 6.9 4.0 - 9.8 13.2 1.8 - 24.5 10.9 8.0 - 13.9 11.1 8.1 - 14.2 23.7 12.6 - 34.8
Texas 1 33.2 31.6 - 34.8 33.8 32.0 - 35.6 28.8 23.3 - 34.4 37.0 35.9 - 38.0 37.3 36.1 - 38.5 29.5 26.4 - 32.7
(NPCR) 3 16.4 15.0 - 17.7 16.3 14.9 - 17.7 12.7 8.7 - 16.7 19.7 18.7 - 20.8 19.8 18.7 - 21.0 13.1 10.2 - 16.0
5 12.0 10.9 - 13.2 11.9 10.6 - 13.2 10.0 6.0 - 14.1 14.1 12.9 - 15.3 14.3 12.9 - 15.6 8.0 5.8 - 10.3
MIDWEST
East North Central
Michigan 1 28.2 25.7 - 30.6 29.5 26.7 - 32.3 24.5 18.4 - 30.6 34.3 32.6 - 36.1 35.6 33.6 - 37.7 27.6 23.5 - 31.6
(NPCR) 3 15.6 13.6 - 17.6 15.9 13.6 - 18.2 14.3 9.3 - 19.4 19.2 17.5 - 20.9 19.8 17.8 - 21.8 16.7 12.8 - 20.6
5 11.0 9.2 - 12.8 11.6 9.5 - 13.7 7.9 4.3 - 11.5 15.2 13.3 - 17.1 16.4 14.2 - 18.6 6.1 4.1 - 8.0
Ohio 1 27.0 24.5 - 29.5 28.4 25.5 - 31.2 24.4 18.4 - 30.5 33.1 31.3 - 34.8 33.5 31.6 - 35.5 29.9 25.4 - 34.4
(NPCR) 3 12.7 10.8 - 14.7 14.1 11.8 - 16.4 7.8 4.3 - 11.2 17.2 15.6 - 18.9 17.1 15.3 - 19.0 15.8 11.9 - 19.6
5 9.1 7.4 - 10.8 10.3 8.2 - 12.3 4.7 2.1 - 7.3 12.7 10.8 - 14.5 12.2 10.2 - 14.3 13.9 10.0 - 17.7
Wisconsin 1 34.4 30.8 - 38.1 34.9 31.1 - 38.8 38.2 24.1 - 52.4 40.5 37.9 - 43.1 41.2 38.4 - 44.1 30.7 21.7 - 39.7
(NPCR) 3 16.8 13.8 - 19.9 16.8 13.5 - 20.0 22.8 10.6 - 35.0 20.4 17.8 - 22.9 20.9 18.1 - 23.6 13.4 7.1 - 19.7
5 13.9 10.9 - 16.9 14.0 10.8 - 17.2 13.9 4.0 - 23.9 11.5 9.0 - 14.1 12.0 9.2 - 14.7 10.1 1.6 - 18.6
West North Central
Iowa 1 27.1 22.0 - 32.2 27.5 22.5 - 32.4 - 38.7 35.2 - 42.2 39.7 36.0 - 43.3 43.5 25.5 - 61.6
(SEER) 3 14.6 10.6 - 18.7 15.5 11.5 - 19.5 - 19.4 16.0 - 22.9 20.7 17.1 - 24.4 19.8 2.2 - 37.3
5 12.0 8.3 - 15.7 12.6 8.9 - 16.3 - 16.5 12.9 - 20.1 17.7 13.9 - 21.5 19.9 2.2 - 37.5
Nebraska 1 32.9 27.0 - 38.8 34.3 28.0 - 40.6 37.0 10.9 - 63.1 40.3 36.2 - 44.3 41.4 37.1 - 45.8 38.8 24.0 - 53.5
(NPCR) 3 17.3 12.6 - 22.0 17.5 12.5 - 22.4 28.5 4.2 - 52.9 19.9 16.0 - 23.8 20.6 16.5 - 24.7 18.5 5.3 - 31.7
5 12.7 8.5 - 16.9 12.6 8.1 - 17.0 23.7 0.0 - 48.2 14.9 11.3 - 18.5 15.3 11.5 - 19.1 19.0 5.5 - 32.5
WEST
Mountain
Colorado 1 29.8 25.7 - 33.8 28.7 24.3 - 33.1 41.2 24.5 - 57.9 37.5 34.7 - 40.4 36.7 33.7 - 39.7 27.8 16.8 - 38.7
(NPCR) 3 13.9 10.9 - 17.0 13.8 10.5 - 17.1 9.8 0.1 - 19.5 20.1 17.5 - 22.8 19.6 16.8 - 22.4 10.9 1.5 - 20.3
5 11.5 8.7 - 14.3 11.3 8.3 - 14.4 6.9 0.0 - 15.0 16.0 13.2 - 18.9 15.6 12.6 - 18.6 11.0 1.5 - 20.5
Idaho 1 31.5 22.5 - 40.5 32.1 22.8 - 41.4 - 36.8 31.5 - 42.2 37.6 32.0 - 43.1 -
(NPCR) 3 18.4 11.2 - 25.6 18.4 10.9 - 25.9 - 19.4 14.2 - 24.6 20.0 14.6 - 25.4 -
5 15.4 8.1 - 22.6 15.2 7.7 - 22.7 - 11.5 6.5 - 16.4 11.8 6.6 - 17.1 -
Montana 1 29.1 19.1 - 39.1 28.6 18.1 - 39.1 - 35.9 29.6 - 42.2 38.2 31.3 - 45.1 -
(NPCR) 3 14.7 7.3 - 22.1 15.2 7.5 - 22.8 - 15.4 9.7 - 21.0 16.8 10.6 - 23.0 -
5 13.9 5.7 - 22.1 13.9 5.2 - 22.7 - 11.1 5.5 - 16.6 11.8 5.9 - 17.8 -
New Mexico 1 27.2 22.4 - 32.0 25.9 20.9 - 31.0 - 32.0 28.6 - 35.3 31.5 27.9 - 35.1 37.2 13.1 - 61.4
(SEER) 3 11.2 7.7 - 14.7 11.0 7.3 - 14.6 - 13.9 11.1 - 16.8 13.4 10.3 - 16.4 18.9 0.0 - 41.2
5 7.0 4.3 - 9.7 6.9 4.0 - 9.7 - 9.7 7.1 - 12.4 9.9 7.0 - 12.9 -
Utah 1 28.8 21.6 - 36.0 29.4 22.0 - 36.9 - 38.7 33.7 - 43.7 40.4 35.0 - 45.7 27.4 3.6 - 51.2
(SEER) 3 13.7 8.3 - 19.1 13.2 7.7 - 18.6 - 18.9 14.3 - 23.6 20.7 15.6 - 25.7 0.2 0.0 - 0.5
5 11.4 6.5 - 16.3 11.7 6.5 - 17.0 - 9.8 5.9 - 13.7 10.7 6.4 - 15.0 -
Wyoming 1 30.4 16.3 - 44.4 32.8 17.8 - 47.7 - 31.8 24.2 - 39.5 32.3 24.6 - 40.0 -
(NPCR) 3 5.4 0.0 - 12.0 5.9 0.0 - 12.9 - 16.0 9.9 - 22.1 16.3 10.1 - 22.5 -
5 2.7 0.0 - 7.0 3.0 0.0 - 7.6 - 8.1 2.2 - 13.9 8.1 2.3 - 14.0 -
Pacific
Alaska 1 33.3 23.4 - 43.2 34.3 22.6 - 46.1 - 38.5 31.6 - 45.4 37.1 28.2 - 46.0 31.5 10.0 - 52.9
(NPCR) 3 11.7 6.2 - 17.2 14.7 6.0 - 23.4 - 25.9 18.9 - 32.8 21.4 14.3 - 28.5 8.1 0.0 - 20.0
5 9.0 3.9 - 14.0 9.8 2.6 - 17.0 - 16.6 9.4 - 23.7 13.1 6.9 - 19.4 -
California 1 32.9 31.7 - 34.1 31.2 29.8 - 32.7 25.6 21.4 - 29.8 39.5 38.7 - 40.3 37.2 36.2 - 38.2 31.5 28.4 - 34.5
(NPCR/SEER) 3 16.3 15.3 - 17.3 14.4 13.3 - 15.6 10.0 7.4 - 12.6 21.1 20.3 - 21.9 18.7 17.7 - 19.6 16.1 13.2 - 18.9
5 11.4 10.6 - 12.3 10.1 9.1 - 11.1 7.2 5.1 - 9.3 14.8 13.8 - 15.8 12.8 11.7 - 13.9 11.7 8.5 - 14.9
Hawaii 1 34.8 29.8 - 39.8 37.3 23.9 - 50.7 - 40.5 36.9 - 44.1 34.3 26.9 - 41.7 53.6 25.1 - 82.2
(SEER) 3 18.2 14.2 - 22.3 21.2 9.7 - 32.7 - 23.1 19.4 - 26.8 23.0 15.9 - 30.1 21.4 0.0 - 44.1
5 15.2 11.3 - 19.1 19.8 8.4 - 31.1 - 13.2 8.8 - 17.6 16.8 9.0 - 24.7 21.8 0.0 - 44.9
Oregon 1 26.8 22.6 - 31.1 25.5 20.9 - 30.1 - 34.7 31.9 - 37.5 33.2 30.2 - 36.2 42.1 26.2 - 57.9
(NPCR) 3 10.2 7.2 - 13.2 8.6 5.7 - 11.6 - 15.7 13.1 - 18.2 14.1 11.3 - 16.8 24.3 8.8 - 39.8
5 6.9 4.3 - 9.5 5.9 3.3 - 8.5 - 11.2 8.7 - 13.8 10.1 7.4 - 12.8 6.3 0.0 - 15.3
Washington 1 32.2 29.0 - 35.4 31.2 27.6 - 34.9 35.8 19.9 - 51.7 40.3 38.1 - 42.5 38.4 35.9 - 40.9 49.0 39.4 - 58.7
(NPCR) 3 15.3 12.8 - 17.8 13.9 11.2 - 16.7 21.1 7.4 - 34.8 22.1 20.0 - 24.2 20.4 18.0 - 22.7 21.6 12.5 - 30.8
5 11.8 9.5 - 14.1 10.7 8.1 - 13.2 12.3 1.6 - 23.1 14.7 12.4 - 17.0 13.9 11.3 - 16.4 8.1 4.6 - 11.7
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SEER 
Summary 
Stage
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
UNITED STATES
All stages 12.2 11.8 - 12.5 11.7 11.3 - 12.1 9.1 8.0 - 10.2 14.8 14.4 - 15.2 14.3 13.8 - 14.8 11.4 10.3 - 12.5
Localized 22.9 22.1 - 23.8 22.4 21.4 - 23.4 15.8 13.3 - 18.2 25.7 24.9 - 26.5 24.8 23.9 - 25.7 20.8 18.4 - 23.3
Regional 8.3 7.6 - 9.0 7.6 6.8 - 8.4 8.3 6.3 - 10.4 9.5 8.8 - 10.2 9.2 8.4 - 9.9 7.1 5.4 - 8.9
Distant 2.8 2.4 - 3.3 2.4 2.0 - 2.9 2.5 1.2 - 3.8 3.5 3.0 - 4.0 2.9 2.3 - 3.4 3.8 2.6 - 5.1
Unknown 8.2 7.6 - 8.9 7.9 7.2 - 8.7 7.0 5.3 - 8.8 8.9 8.2 - 9.6 9.0 8.1 - 9.8 6.2 4.6 - 7.8
NORTHEAST
New England
Connecticut All stages 12.4 9.2 - 15.5 12.8 9.4 - 16.2 13.5 3.4 - 23.5 14.5 11.4 - 17.7 14.9 11.4 - 18.5 16.1 7.7 - 24.4
(SEER) Localized 23.6 17.0 - 30.2 25.3 18.2 - 32.4 8.9 0.0 - 22.0 23.7 17.2 - 30.3 23.6 16.6 - 30.6 22.4 6.2 - 38.6
Regional 7.7 3.4 - 11.9 4.3 1.3 - 7.2 34.3 8.8 - 59.8 8.1 4.7 - 11.5 8.8 4.8 - 12.8 -
Distant 1.6 0.0 - 3.8 0.0 0.0 - 0.0 - 5.8 2.6 - 9.0 4.1 0.6 - 7.6 15.1 0.5 - 29.7
Unknown 8.6 3.9 - 13.2 9.6 4.5 - 14.8 0.0 - 9.5 6.0 - 13.1 9.3 5.7 - 13.0 -
Massachusetts All stages 14.0 11.7 - 16.4 13.1 10.6 - 15.5 10.3 3.4 - 17.2 15.6 13.0 - 18.2 13.6 10.9 - 16.4 20.3 13.0 - 27.6
(NPCR) Localized 31.0 25.4 - 36.6 28.5 22.9 - 34.0 22.2 3.7 - 40.7 28.1 23.0 - 33.2 26.5 21.1 - 31.9 14.6 0.0 - 32.5
Regional 8.0 4.6 - 11.4 7.9 4.6 - 11.3 9.9 0.0 - 21.0 10.5 6.7 - 14.4 9.5 5.6 - 13.4 9.3 0.0 - 20.2
Distant 2.6 0.5 - 4.6 2.2 0.4 - 4.0 0.0 - 4.7 2.4 - 7.0 2.2 0.0 - 4.5 -
Unknown 3.8 1.4 - 6.1 2.8 1.1 - 4.6 0.0 - 3.9 1.8 - 6.0 1.6 0.5 - 2.8 10.0 0.0 - 20.9
New Hampshire All stages 12.2 6.9 - 17.5 10.9 5.7 - 16.1 - 12.5 8.6 - 16.4 12.4 8.3 - 16.4 -
(NPCR) Localized 32.9 16.2 - 49.5 33.7 15.8 - 51.6 - 24.2 15.9 - 32.4 25.6 17.2 - 34.1 -
Regional 10.1 0.2 - 20.0 4.3 0.0 - 10.8 - 10.0 2.6 - 17.3 8.7 1.6 - 15.9 -
Distant 0.0 - 0.0 - - - - -
Unknown 2.3 0.0 - 6.1 2.5 0.0 - 6.5 - 3.5 0.0 - 8.5 4.0 0.0 - 9.6 -
Rhode Island All stages 12.8 7.7 - 17.8 11.7 6.8 - 16.6 20.6 0.0 - 42.9 10.7 6.8 - 14.7 9.9 6.1 - 13.6 14.3 0.0 - 31.3
(NPCR) Localized 22.2 10.0 - 34.5 19.8 7.5 - 32.1 - - - -
Regional 11.3 2.4 - 20.3 12.5 2.7 - 22.4 - - - -
Distant 8.5 0.0 - 18.2 5.7 0.0 - 14.2 - - - -
Unknown 4.5 0.0 - 10.2 4.6 0.0 - 10.4 - - - -
Mid Atlantic
New Jersey All stages 12.6 10.7 - 14.4 12.3 10.2 - 14.4 6.9 3.8 - 10.0 14.8 12.8 - 16.8 15.4 13.1 - 17.6 8.8 4.2 - 13.4
(NPCR/SEER) Localized 23.4 19.3 - 27.4 23.0 18.3 - 27.7 21.7 11.2 - 32.2 23.9 20.1 - 27.6 25.0 20.8 - 29.2 16.5 7.1 - 25.9
Regional 7.9 4.7 - 11.1 9.0 5.2 - 12.8 2.5 0.0 - 6.5 10.0 6.5 - 13.5 9.3 5.6 - 12.9 11.2 3.3 - 19.0
Distant 0.9 0.0 - 1.8 1.2 0.0 - 2.5 0.0 - 3.4 1.6 - 5.2 4.1 2.0 - 6.2 2.2 0.0 - 5.0
Unknown 12.0 8.6 - 15.3 10.2 7.0 - 13.5 13.3 3.5 - 23.0 11.1 7.7 - 14.5 12.0 7.9 - 16.0 -
New York All stages 16.8 15.5 - 18.2 14.6 13.1 - 16.2 13.1 9.9 - 16.4 20.4 19.1 - 21.7 18.2 16.6 - 19.8 16.5 13.5 - 19.5
(NPCR) Localized 32.0 28.8 - 35.2 30.3 26.5 - 34.1 18.2 11.3 - 25.2 34.0 31.4 - 36.7 30.2 27.0 - 33.4 30.2 23.9 - 36.4
Regional 14.9 12.2 - 17.6 11.0 8.1 - 13.8 18.5 11.7 - 25.3 13.9 11.6 - 16.2 13.1 10.3 - 15.9 12.2 8.0 - 16.5
Distant 5.9 4.1 - 7.8 4.0 2.2 - 5.8 3.3 1.3 - 5.3 5.3 3.7 - 6.8 4.1 2.6 - 5.6 9.1 5.3 - 12.9
Unknown 10.5 8.6 - 12.4 8.7 6.5 - 10.9 9.0 4.3 - 13.7 13.5 11.1 - 16.0 13.6 10.8 - 16.5 4.1 1.7 - 6.5
Pennsylvania All stages 12.3 10.7 - 13.9 12.2 10.4 - 14.0 7.9 4.8 - 11.1 15.1 13.5 - 16.8 14.7 12.8 - 16.5 13.4 10.2 - 16.5
(NPCR) Localized 23.5 19.9 - 27.0 23.6 19.6 - 27.5 9.9 5.2 - 14.5 25.4 22.1 - 28.7 25.6 21.9 - 29.3 23.4 16.2 - 30.6
Regional 7.8 5.3 - 10.3 7.2 4.5 - 9.8 8.1 2.2 - 14.1 8.7 6.4 - 11.1 9.4 6.6 - 12.2 10.6 5.4 - 15.7
Distant 1.5 0.3 - 2.6 1.3 0.0 - 2.6 0.0 0.0 - 0.0 5.4 3.5 - 7.2 4.5 2.7 - 6.4 5.1 1.1 - 9.1
Unknown 9.2 6.2 - 12.3 6.7 3.8 - 9.6 8.7 2.9 - 14.5 8.0 5.2 - 10.9 5.9 3.2 - 8.6 11.5 2.8 - 20.2
SOUTH
South Atlantic
Delaware All stages 12.1 5.8 - 18.3 13.3 6.3 - 20.3 7.6 0.0 - 18.9 14.5 8.0 - 21.1 13.5 7.1 - 19.9 16.8 3.0 - 30.5
(NPCR) Localized 25.5 11.1 - 39.8 27.8 11.4 - 44.2 - 24.7 13.0 - 36.4 17.5 9.6 - 25.3 40.5 13.6 - 67.5
Regional 10.2 0.0 - 22.2 15.6 0.0 - 33.5 - 0.0 0.0 - 0.1 9.1 0.0 - 19.0 0.7 0.0 - 2.3
Distant 0.0 - 0.0 - - - - -
Unknown 0.0 - 0.0 - - 5.9 0.0 - 14.5 8.4 0.0 - 20.5 -
Florida All stages 14.8 13.3 - 16.2 14.5 12.9 - 16.1 14.3 9.0 - 19.6 20.9 19.3 - 22.4 20.8 19.1 - 22.6 17.4 13.7 - 21.1
(NPCR) Localized 26.4 23.0 - 29.7 26.8 23.2 - 30.4 14.8 6.6 - 22.9 32.8 29.9 - 35.6 32.7 29.7 - 35.7 30.3 22.3 - 38.3
Regional 10.7 7.9 - 13.5 9.4 6.6 - 12.2 15.8 6.7 - 24.8 14.8 11.8 - 17.7 14.5 11.3 - 17.8 9.5 4.9 - 14.1
Distant 5.5 3.4 - 7.5 4.7 2.7 - 6.7 6.9 0.7 - 13.1 8.1 5.8 - 10.4 7.0 4.6 - 9.3 9.7 3.3 - 16.1
Unknown 12.5 10.1 - 15.0 12.4 9.7 - 15.0 14.4 6.5 - 22.3 16.3 13.3 - 19.2 16.4 13.0 - 19.7 11.2 6.0 - 16.5
Georgia All stages 7.6 5.6 - 9.6 8.2 5.7 - 10.6 4.5 1.7 - 7.2 12.5 10.4 - 14.6 13.3 10.8 - 15.7 10.9 6.3 - 15.4
(NPCR/SEER) Localized 16.5 11.9 - 21.2 19.4 13.7 - 25.1 6.9 1.5 - 12.2 22.7 18.6 - 26.9 22.7 18.0 - 27.3 24.4 15.3 - 33.6
Regional 2.4 0.0 - 4.9 2.6 0.0 - 5.9 2.0 0.0 - 5.2 6.4 3.7 - 9.2 8.3 4.8 - 11.8 4.4 1.7 - 7.0
Distant 0.0 0.0 - 0.0 0.0 0.0 - 0.0 0.1 0.0 - 0.3 4.1 1.8 - 6.4 5.0 2.1 - 7.8 3.3 0.0 - 6.8
Unknown 5.5 2.5 - 8.5 3.2 1.0 - 5.3 9.2 0.5 - 17.8 8.4 4.6 - 12.2 8.0 4.1 - 11.9 8.7 0.0 - 18.1
Maryland All stages 10.7 8.1 - 13.3 9.7 6.7 - 12.7 10.8 6.1 - 15.5 13.4 10.8 - 16.0 13.5 10.6 - 16.5 8.9 5.0 - 12.7
(NPCR) Localized - - - - - -
Regional - - - - - -
Distant - - - - - -
Unknown - - - - - -
95% CI95% CI 95% CI 95% CI 95% CI 95% CI
2001-2003 2004-2009
All races White Black All races White Black
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SEER 
Summary 
Stage
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%) 95% CI95% CI 95% CI 95% CI 95% CI 95% CI
2001-2003 2004-2009
All races White Black All races White Black
North Carolina All stages 10.2 8.1 - 12.4 10.7 8.2 - 13.2 5.7 2.8 - 8.6 12.0 9.9 - 14.1 13.3 10.8 - 15.9 5.9 2.5 - 9.3
(NPCR) Localized 17.5 13.1 - 21.8 17.6 12.7 - 22.5 9.7 3.3 - 16.2 21.7 17.2 - 26.2 25.3 19.9 - 30.6 6.4 3.0 - 9.9
Regional 6.7 3.2 - 10.1 5.1 1.8 - 8.4 11.9 2.6 - 21.1 6.2 3.5 - 8.9 6.0 3.0 - 9.0 3.2 0.0 - 7.3
Distant 2.7 0.8 - 4.6 3.3 1.1 - 5.4 0.0 - 3.4 1.2 - 5.6 3.1 0.9 - 5.2 -
Unknown 7.4 3.9 - 10.8 8.0 4.1 - 12.0 1.9 0.3 - 3.6 6.0 2.9 - 9.0 4.6 2.1 - 7.2 10.3 2.2 - 18.5
South Carolina All stages 10.0 7.2 - 12.7 11.6 8.2 - 15.1 6.7 2.2 - 11.1 10.4 7.7 - 13.1 11.9 8.5 - 15.2 6.5 2.5 - 10.4
(NPCR) Localized 18.2 12.7 - 23.7 20.0 13.4 - 26.5 12.7 1.3 - 24.2 20.8 15.4 - 26.2 24.5 18.2 - 30.9 13.5 5.1 - 21.9
Regional 7.9 3.1 - 12.8 10.6 4.5 - 16.7 5.4 0.0 - 13.8 4.3 1.4 - 7.1 3.8 0.0 - 7.8 0.1 0.0 - 0.2
Distant 0.0 - 0.0 - 0.0 - 3.5 0.1 - 6.8 5.2 0.3 - 10.1 -
Unknown 4.8 1.9 - 7.8 4.2 1.0 - 7.4 7.6 0.0 - 15.5 6.0 2.8 - 9.2 5.3 0.4 - 10.2 6.0 0.0 - 13.4
West Virginia All stages 6.3 3.1 - 9.5 6.6 3.3 - 10.0 - 9.2 5.4 - 13.1 7.9 4.5 - 11.4 9.0 0.0 - 21.3
(NPCR) Localized 11.5 2.9 - 20.1 11.9 3.0 - 20.8 - 16.2 8.7 - 23.7 16.9 9.1 - 24.7 -
Regional 15.6 3.6 - 27.6 16.1 3.8 - 28.3 - 15.2 6.0 - 24.5 15.2 5.9 - 24.5 -
Distant 3.0 0.0 - 7.4 3.1 0.0 - 7.7 - 8.3 1.5 - 15.1 9.0 1.7 - 16.3 -
Unknown 0.0 - 0.0 - - 2.2 0.0 - 5.5 2.0 0.0 - 5.0 -
East South Central
Alabama All stages 8.3 5.6 - 10.9 7.3 4.5 - 10.0 7.8 3.3 - 12.3 9.8 7.3 - 12.3 11.4 8.2 - 14.6 4.5 1.4 - 7.7
(NPCR) Localized 15.1 9.7 - 20.5 13.2 7.5 - 18.9 24.2 9.9 - 38.6 19.7 15.4 - 24.0 20.3 15.9 - 24.6 13.9 4.1 - 23.8
Regional 5.3 1.3 - 9.2 5.5 1.0 - 10.0 4.3 0.0 - 11.0 3.4 1.2 - 5.6 5.5 2.6 - 8.5 0.1 0.0 - 0.3
Distant 3.4 0.0 - 7.9 1.1 0.0 - 2.4 0.0 - 2.8 0.0 - 5.7 3.2 0.1 - 6.3 0.3 0.0 - 0.9
Unknown 4.7 1.5 - 7.9 4.0 0.8 - 7.1 6.0 0.0 - 13.0 2.8 0.5 - 5.1 3.8 1.0 - 6.5 0.1 0.0 - 0.3
Kentucky All stages 10.3 7.4 - 13.2 10.3 7.3 - 13.3 11.9 1.8 - 21.9 11.2 8.5 - 14.0 11.6 8.6 - 14.5 9.8 1.8 - 17.8
(NPCR/SEER) Localized 21.9 15.7 - 28.2 21.8 15.4 - 28.2 24.2 2.8 - 45.6 18.8 13.7 - 24.0 20.0 15.0 - 25.1 16.5 1.6 - 31.4
Regional 2.2 0.0 - 4.5 1.4 0.0 - 3.6 8.3 0.0 - 20.9 10.6 6.5 - 14.6 11.6 7.3 - 16.0 -
Distant 0.0 0.0 - 0.0 0.0 0.0 - 0.0 - 2.1 0.3 - 3.9 1.8 0.0 - 4.3 6.4 0.0 - 14.1
Unknown 6.2 3.3 - 9.2 7.0 3.8 - 10.2 - 4.4 1.5 - 7.3 2.9 0.5 - 5.4 -
Mississippi All stages 7.1 2.6 - 11.6 8.0 2.8 - 13.2 3.7 0.0 - 9.3 11.3 8.0 - 14.6 13.5 9.6 - 17.4 8.6 3.6 - 13.5
(NPCR) Localized 12.1 2.3 - 21.9 13.3 1.5 - 25.1 10.4 0.0 - 25.6 23.3 16.7 - 29.8 24.7 17.2 - 32.2 19.2 5.5 - 32.8
Regional 12.2 0.2 - 24.2 11.8 0.0 - 25.5 - 5.1 1.0 - 9.2 3.7 0.0 - 8.0 4.8 0.0 - 10.8
Distant 0.0 - 0.0 - - 3.8 0.2 - 7.5 5.2 0.4 - 9.9 -
Unknown 0.0 - 0.0 - - 3.7 0.0 - 8.5 3.2 0.0 - 7.8 16.0 2.0 - 30.0
Tennessee All stages 8.2 4.6 - 11.7 10.0 5.9 - 14.1 0.0 - 11.5 9.0 - 13.9 10.7 8.2 - 13.2 12.0 5.9 - 18.1
(NPCR) Localized 14.6 7.8 - 21.3 19.0 9.0 - 29.0 - 20.4 15.8 - 25.0 18.6 13.9 - 23.4 24.2 12.9 - 35.5
Regional 5.4 0.0 - 11.8 6.0 0.0 - 13.1 - 6.6 3.7 - 9.6 7.5 3.9 - 11.1 0.2 0.0 - 0.7
Distant 3.5 0.0 - 8.8 4.3 0.0 - 10.8 - 0.0 0.0 - 0.1 0.0 0.0 - 0.1 5.8 0.0 - 12.5
Unknown 3.3 0.0 - 8.4 4.0 0.0 - 10.0 - 6.2 2.7 - 9.8 3.9 0.5 - 7.3 0.3 0.0 - 1.0
West South Central
Louisiana All stages 9.1 6.8 - 11.4 11.9 8.9 - 15.0 5.0 2.1 - 7.9 9.3 7.1 - 11.6 11.1 8.1 - 14.0 6.8 3.4 - 10.2
(NPCR/SEER) Localized 17.9 13.2 - 22.7 21.8 16.0 - 27.6 11.4 4.2 - 18.7 15.1 11.2 - 19.0 17.8 12.8 - 22.8 11.2 5.4 - 17.0
Regional 4.1 1.3 - 7.0 4.9 1.2 - 8.5 1.9 0.0 - 4.9 6.2 3.4 - 8.9 8.4 4.8 - 12.0 2.5 0.0 - 5.3
Distant 0.0 0.0 - 0.0 0.0 0.0 - 0.0 0.0 - 2.3 0.6 - 4.0 0.0 0.0 - 0.0 4.4 0.1 - 8.7
Unknown 5.0 1.2 - 8.8 4.2 0.0 - 8.5 3.3 0.0 - 8.5 5.3 1.0 - 9.7 6.0 0.4 - 11.7 4.2 0.0 - 9.3
Oklahoma All stages 8.1 5.4 - 10.8 6.9 4.0 - 9.8 13.2 1.8 - 24.5 10.9 8.0 - 13.9 11.1 8.1 - 14.2 23.7 12.6 - 34.8
(NPCR) Localized 15.6 10.1 - 21.2 12.8 7.4 - 18.1 - 17.3 11.7 - 22.8 18.6 12.9 - 24.3 22.8 0.0 - 46.4
Regional 3.8 0.0 - 8.2 2.5 0.0 - 6.4 - 3.5 0.6 - 6.5 5.0 1.3 - 8.8 8.7 0.0 - 21.1
Distant 1.2 0.0 - 3.0 0.0 0.0 - 0.0 - 3.7 0.4 - 7.0 3.7 0.4 - 6.9 13.1 0.0 - 27.0
Unknown 7.2 3.5 - 11.0 6.3 1.3 - 11.3 13.8 0.0 - 29.5 11.0 7.3 - 14.6 9.9 6.2 - 13.7 27.3 5.8 - 48.7
Texas All stages 12.0 10.9 - 13.2 11.9 10.6 - 13.2 10.0 6.0 - 14.1 14.1 12.9 - 15.3 14.3 12.9 - 15.6 8.0 5.8 - 10.3
(NPCR) Localized 19.5 17.0 - 22.0 19.0 16.3 - 21.7 16.3 9.3 - 23.3 22.6 20.3 - 24.9 22.2 19.7 - 24.7 15.1 10.0 - 20.1
Regional 7.5 5.3 - 9.8 6.6 4.3 - 8.9 7.9 1.3 - 14.5 7.9 5.8 - 10.0 8.4 6.1 - 10.7 3.7 1.1 - 6.3
Distant 3.7 2.2 - 5.2 3.7 2.1 - 5.4 2.3 0.2 - 4.3 3.0 1.9 - 4.2 3.1 1.8 - 4.3 4.4 1.4 - 7.4
Unknown 11.4 9.4 - 13.4 11.0 8.9 - 13.1 8.0 2.0 - 14.0 12.2 10.0 - 14.4 12.6 10.2 - 15.0 10.2 6.4 - 13.9
MIDWEST
East North Central
Michigan All stages 11.0 9.2 - 12.8 11.6 9.5 - 13.7 7.9 4.3 - 11.5 15.2 13.3 - 17.1 16.4 14.2 - 18.6 6.1 4.1 - 8.0
(NPCR) Localized 23.9 19.3 - 28.4 24.5 19.4 - 29.5 14.2 6.2 - 22.1 26.7 22.2 - 31.2 28.3 23.4 - 33.2 13.5 9.3 - 17.8
Regional 7.2 4.3 - 10.2 7.9 4.7 - 11.0 9.1 1.8 - 16.4 16.2 11.7 - 20.7 16.3 11.1 - 21.5 9.6 1.4 - 17.8
Distant 1.6 0.3 - 2.8 1.7 0.3 - 3.1 3.1 0.0 - 6.9 5.7 3.5 - 7.9 5.4 3.0 - 7.7 2.5 0.0 - 5.6
Unknown 6.1 3.8 - 8.5 4.7 2.7 - 6.7 6.9 0.6 - 13.3 7.9 5.7 - 10.1 8.9 6.2 - 11.5 4.0 0.1 - 7.9
Ohio All stages 9.1 7.4 - 10.8 10.3 8.2 - 12.3 4.7 2.1 - 7.3 12.7 10.8 - 14.5 12.2 10.2 - 14.3 13.9 10.0 - 17.7
(NPCR) Localized 17.9 13.8 - 22.0 18.8 14.1 - 23.5 15.0 5.6 - 24.3 28.9 24.6 - 33.1 29.0 24.2 - 33.7 28.2 19.6 - 36.7
Regional 5.6 3.0 - 8.2 6.9 3.6 - 10.3 5.6 0.0 - 12.3 8.3 5.6 - 11.0 8.9 5.7 - 12.1 12.1 5.8 - 18.4
Distant 1.7 0.4 - 3.1 1.9 0.3 - 3.4 0.0 - 3.3 1.2 - 5.3 2.9 1.1 - 4.8 5.3 0.0 - 10.7
Unknown 6.5 4.1 - 8.9 8.2 5.5 - 10.9 3.0 0.0 - 6.5 2.9 1.3 - 4.5 2.3 0.8 - 3.7 2.0 0.3 - 3.8
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SEER 
Summary 
Stage
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%) 95% CI95% CI 95% CI 95% CI 95% CI 95% CI
2001-2003 2004-2009
All races White Black All races White Black
Wisconsin All stages 13.9 10.9 - 16.9 14.0 10.8 - 17.2 13.9 4.0 - 23.9 11.5 9.0 - 14.1 12.0 9.2 - 14.7 10.1 1.6 - 18.6
(NPCR) Localized - - - - - -
Regional - - - - - -
Distant - - - - - -
Unknown - - - - - -
West North Central
Iowa All stages 12.0 8.3 - 15.7 12.6 8.9 - 16.3 - 16.5 12.9 - 20.1 17.7 13.9 - 21.5 19.9 2.2 - 37.5
(SEER) Localized 31.9 23.8 - 40.0 32.8 24.3 - 41.3 - 38.7 30.9 - 46.5 40.4 32.6 - 48.2 -
Regional 1.2 0.0 - 3.0 1.2 0.0 - 3.0 - 9.1 5.3 - 12.8 9.9 6.0 - 13.7 -
Distant 1.8 0.0 - 4.9 2.0 0.0 - 5.3 - 1.3 0.0 - 3.2 - -
Unknown 1.8 0.0 - 4.6 1.9 0.0 - 5.0 - 2.7 0.0 - 5.9 2.7 0.0 - 6.0 -
Nebraska All stages 12.7 8.5 - 16.9 12.6 8.1 - 17.0 23.7 0.0 - 48.2 14.9 11.3 - 18.5 15.3 11.5 - 19.1 19.0 5.5 - 32.5
(NPCR) Localized 23.7 15.3 - 32.1 23.5 14.4 - 32.6 - 26.5 19.5 - 33.5 25.7 18.6 - 32.8 52.8 17.3 - 88.3
Regional 12.5 3.4 - 21.6 14.4 3.9 - 24.8 - 12.2 7.5 - 16.9 14.1 7.0 - 21.1 15.5 0.0 - 32.8
Distant 3.6 0.0 - 8.8 0.0 - - - - -
Unknown 4.5 0.0 - 9.1 4.7 0.0 - 9.5 - 6.9 0.7 - 13.0 7.5 0.8 - 14.2 -
WEST
Mountain
Colorado All stages 11.5 8.7 - 14.3 11.3 8.3 - 14.4 6.9 0.0 - 15.0 16.0 13.2 - 18.9 15.6 12.6 - 18.6 11.0 1.5 - 20.5
(NPCR) Localized 20.5 15.1 - 25.9 20.4 14.7 - 26.2 - 28.2 22.3 - 34.1 27.0 20.9 - 33.2 19.0 0.8 - 37.3
Regional 7.7 3.5 - 12.0 7.6 3.1 - 12.1 0.0 - 6.4 3.2 - 9.6 5.9 2.7 - 9.0 15.2 0.0 - 34.1
Distant 3.6 0.7 - 6.4 0.6 0.0 - 1.3 - 3.0 0.2 - 5.9 3.2 0.2 - 6.1 -
Unknown 5.3 2.4 - 8.2 6.4 3.0 - 9.8 - 8.9 4.9 - 13.0 8.4 4.3 - 12.4 -
Idaho All stages 15.4 8.1 - 22.6 15.2 7.7 - 22.7 - 11.5 6.5 - 16.4 11.8 6.6 - 17.1 -
(NPCR) Localized 37.0 18.1 - 56.0 36.1 16.5 - 55.6 - 22.1 12.0 - 32.2 23.1 12.4 - 33.7 -
Regional 4.0 0.0 - 10.0 4.0 0.0 - 10.0 - 6.9 0.0 - 15.1 6.9 0.0 - 15.1 -
Distant 6.7 0.0 - 16.7 7.6 0.0 - 18.8 - 1.0 0.0 - 3.4 1.0 0.0 - 3.2 -
Unknown 6.0 0.0 - 15.3 6.0 0.0 - 15.3 - 0.7 0.0 - 2.3 0.9 0.0 - 2.7 -
Montana All stages 13.9 5.7 - 22.1 13.9 5.2 - 22.7 - 11.1 5.5 - 16.6 11.8 5.9 - 17.8 -
(NPCR) Localized 27.3 7.9 - 46.7 32.1 10.0 - 54.3 - 16.4 6.1 - 26.8 16.4 5.8 - 26.9 -
Regional 6.8 0.0 - 16.6 7.6 0.0 - 18.6 - 8.1 0.0 - 16.2 8.8 0.0 - 17.9 -
Distant - - - - - -
Unknown 13.0 0.6 - 25.4 10.1 0.0 - 21.7 - 21.3 2.2 - 40.4 20.8 0.6 - 41.1 -
New Mexico All stages 7.0 4.3 - 9.7 6.9 4.0 - 9.7 - 9.7 7.1 - 12.4 9.9 7.0 - 12.9 -
(SEER) Localized 11.5 6.5 - 16.4 11.6 6.3 - 16.9 - 17.0 11.6 - 22.3 15.9 10.6 - 21.3 -
Regional 2.3 0.0 - 5.6 0.0 - - 0.0 0.0 - 0.0 2.2 0.0 - 5.2 -
Distant 4.8 0.8 - 8.9 4.9 0.9 - 8.9 - 5.5 1.3 - 9.6 4.6 0.5 - 8.7 -
Unknown 3.0 0.0 - 6.2 3.3 0.0 - 6.8 - 6.8 2.4 - 11.2 6.6 1.9 - 11.3 -
Utah All stages 11.4 6.5 - 16.3 11.7 6.5 - 17.0 - 9.8 5.9 - 13.7 10.7 6.4 - 15.0 -
(SEER) Localized 16.8 9.6 - 24.1 18.8 10.5 - 27.2 - 23.9 17.3 - 30.5 23.0 16.1 - 29.8 -
Regional 12.5 1.8 - 23.2 8.9 0.0 - 19.2 - 2.9 0.0 - 7.4 3.4 0.0 - 8.8 -
Distant 0.0 - 0.0 - - 1.0 0.0 - 3.4 1.2 0.0 - 4.0 -
Unknown 5.5 0.0 - 13.9 6.1 0.0 - 15.4 - 0.0 - 0.0 - -
Wyoming All stages 2.7 0.0 - 7.0 3.0 0.0 - 7.6 - 8.1 2.2 - 13.9 8.1 2.3 - 14.0 -
(NPCR) Localized - - - 15.9 5.3 - 26.6 15.7 5.2 - 26.3 -
Regional - - - - - -
Distant - - - - 0.0 - -
Unknown 0.0 - 0.0 - - 6.5 0.0 - 15.9 6.8 0.0 - 16.6 -
Pacific
Alaska All stages 9.0 3.9 - 14.0 9.8 2.6 - 17.0 - 16.6 9.4 - 23.7 13.1 6.9 - 19.4 -
(NPCR) Localized 26.1 10.1 - 42.0 22.0 2.0 - 42.0 - 34.8 20.4 - 49.2 46.1 29.1 - 63.2 -
Regional 4.6 0.0 - 11.6 7.8 0.0 - 19.4 - 3.0 0.0 - 7.5 4.8 0.0 - 12.0 -
Distant 5.6 0.0 - 14.1 10.0 0.0 - 24.6 - 0.0 0.0 - 0.0 0.1 0.0 - 0.5 -
Unknown 7.5 0.0 - 16.2 4.1 0.0 - 10.4 - 10.0 0.0 - 21.9 0.0 0.0 - 0.0 -
California All stages 11.4 10.6 - 12.3 10.1 9.1 - 11.1 7.2 5.1 - 9.3 14.8 13.8 - 15.8 12.8 11.7 - 13.9 11.7 8.5 - 14.9
(NPCR/SEER) Localized 21.8 20.0 - 23.6 18.9 16.8 - 20.9 13.9 9.1 - 18.7 26.1 24.1 - 28.0 22.6 20.4 - 24.8 25.1 19.0 - 31.3
Regional 7.8 6.4 - 9.2 7.5 5.7 - 9.3 5.0 2.1 - 7.8 10.1 8.6 - 11.6 8.8 7.1 - 10.4 5.9 2.3 - 9.5
Distant 1.9 1.1 - 2.6 1.8 0.9 - 2.8 3.4 0.0 - 7.0 1.7 1.0 - 2.4 1.4 0.7 - 2.1 3.3 0.7 - 5.9
Unknown 3.8 2.5 - 5.1 3.9 2.3 - 5.5 1.1 0.0 - 2.4 5.8 4.2 - 7.3 5.5 3.7 - 7.3 4.4 0.0 - 10.3
Hawaii All stages 15.2 11.3 - 19.1 19.8 8.4 - 31.1 - 13.2 8.8 - 17.6 16.8 9.0 - 24.7 21.8 0.0 - 44.9
(SEER) Localized 31.4 23.9 - 38.9 43.2 21.5 - 65.0 - 27.0 18.7 - 35.3 31.4 11.1 - 51.6 -
Regional 6.9 2.7 - 11.2 5.9 0.0 - 14.9 - 4.5 0.0 - 10.0 11.6 1.4 - 21.8 -
Distant 1.0 0.0 - 2.1 - - 1.4 0.0 - 3.4 5.4 0.0 - 12.7 -
Unknown 0.0 - - - 0.1 0.0 - 0.3 7.5 0.0 - 18.2 -
Table 3 – Age-std net survival by stage, state and race – Liver Page 3 of 4 Produced 29 July 2016
Page 34 of 35Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
SEER 
Summary 
Stage
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%)
NS 
(%) 95% CI95% CI 95% CI 95% CI 95% CI 95% CI
2001-2003 2004-2009
All races White Black All races White Black
Oregon All stages 6.9 4.3 - 9.5 5.9 3.3 - 8.5 - 11.2 8.7 - 13.8 10.1 7.4 - 12.8 6.3 0.0 - 15.3
(NPCR) Localized 13.4 6.8 - 20.0 10.5 4.2 - 16.8 - 22.8 16.9 - 28.7 20.0 14.0 - 26.0 0.0 0.0 - 0.1
Regional 8.0 2.6 - 13.3 10.1 3.5 - 16.8 - 7.9 4.5 - 11.3 7.2 3.6 - 10.7 0.1 0.0 - 0.2
Distant 1.9 0.0 - 4.0 2.2 0.0 - 4.5 - 2.8 0.1 - 5.4 3.9 0.7 - 7.0 -
Unknown 3.6 0.7 - 6.5 2.0 0.0 - 4.1 - 4.2 0.5 - 8.0 3.7 0.4 - 7.0 -
Washington All stages 11.8 9.5 - 14.1 10.7 8.1 - 13.2 12.3 1.6 - 23.1 14.7 12.4 - 17.0 13.9 11.3 - 16.4 8.1 4.6 - 11.7
(NPCR) Localized 23.9 18.9 - 28.8 24.4 18.7 - 30.1 22.9 1.7 - 44.0 28.1 23.1 - 33.0 28.2 22.7 - 33.7 13.2 0.0 - 27.5
Regional 6.4 3.5 - 9.4 4.1 1.5 - 6.6 6.8 0.0 - 17.0 7.4 4.8 - 10.1 5.3 2.9 - 7.8 5.5 0.0 - 12.9
Distant 1.9 0.3 - 3.6 1.6 0.1 - 3.1 - 0.9 0.0 - 2.2 1.2 0.0 - 2.7 -
Unknown 1.5 0.0 - 3.0 1.8 0.0 - 3.6 - 5.6 2.4 - 8.9 5.1 1.7 - 8.5 -
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